Filgrastim - SYGNIS Pharma

Drug Profile

Filgrastim - SYGNIS Pharma

Alternative Names: AX200; G-CSF - SYGNIS Pharma

Latest Information Update: 31 Jul 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Max Planck Institute of Experimental Medicine
  • Developer SYGNIS Pharma
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants
  • Mechanism of Action Granulocyte colony stimulating factor stimulants; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries; Amyotrophic lateral sclerosis
  • Available For Licensing Yes - Amyotrophic lateral sclerosis; Spinal cord injuries

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Spinal cord injuries; Stroke

Most Recent Events

  • 08 Aug 2013 Biomarkers information updated
  • 25 Jul 2012 Discontinued - Preclinical for Amyotrophic lateral sclerosis in European Union (IV)
  • 25 Jul 2012 Discontinued - Preclinical for Spinal cord injuries in European Union (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top